Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail V. Matthews – 17 September 2016 – While interferon‐based therapy has excellent efficacy in acute and recent hepatitis C virus (HCV) infection, the side effect profile limits implementation. Sofosbuvir and ribavirin for 12‐24 weeks is safe and well tolerated in chronic HCV, with efficacy dependent on genotype and disease stage.

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

Salvatore Petta, Vincent Wai‐Sun Wong, Calogero Cammà, Jean‐Baptiste Hiriart, Grace Lai‐Hung Wong, Fabio Marra, Julien Vergniol, Anthony Wing‐Hung Chan, Vito Di Marco, Wassil Merrouche, Henry Lik‐Yuen Chan, Marco Barbara, Brigitte Le‐Bail, Umberto Arena, Antonio Craxì, Victor de Ledinghen – 17 September 2016 – Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid–fed mouse model of cholestasis

Supriya R. Kulkarni, Carol J. Soroka, Lee R. Hagey, James L. Boyer – 17 September 2016 – Sirtuin1 (Sirt1; mammalian homolog of Saccharomyces cerevisiae enzyme Sir2) is a transcriptional and transactivational regulator of murine farnesoid X receptor (Fxr), which is the primary bile acid (BA) sensor, and critical regulator of BA metabolism in physiological and pathophysiological conditions. Previous studies have suggested compromised Sirt1 expression in rodent models of cholestatic liver injury. We hypothesized that Sirt1 could be potentially targeted to alleviate cholestatic liver injury.

Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis

Benjamin Lelouvier, Florence Servant, Sandrine Païssé, Anne‐Claire Brunet, Salah Benyahya, Matteo Serino, Carine Valle, Maria Rosa Ortiz, Josep Puig, Michael Courtney, Massimo Federici, José‐Manuel Fernández‐Real, Rémy Burcelin, Jacques Amar – 17 September 2016 – The early detection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical need.

Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination

Amalia Azzariti, Serena Mancarella, Letizia Porcelli, Anna Elisa Quatrale, Alessandra Caligiuri, Luigi Lupo, Francesco Dituri, Gianluigi Giannelli – 17 September 2016 – In patients with hepatocellular carcinoma (HCC) receiving sorafenib, drug resistance is common. HCC develops in a microenvironment enriched with extracellular matrix proteins including laminin (Ln)‐332, produced by hepatic stellate cells (HSCs). Ln‐332 is the ligand of α3β1 and α6β4 integrins, differently expressed on the HCC cell surface, that deliver intracellular pathways.

Subscribe to